The next-generation dual-agonist — Tirzepatide targets both GLP-1 and GIP receptors for enhanced appetite suppression and the greatest average weight loss of any non-surgical option available.
Tirzepatide is a dual GLP-1 and GIP receptor agonist — the first of its class to target both incretin hormones simultaneously. By activating both pathways, Tirzepatide achieves greater appetite suppression, better glycemic regulation, and superior weight loss outcomes compared to single-agonist GLP-1 therapies.
Clinical trials demonstrated average weight loss of approximately 20% of body weight with Tirzepatide at the highest dose — significantly greater than Semaglutide. For patients seeking maximum efficacy, Tirzepatide is currently the most powerful non-surgical weight loss medication available.
The same 3-month bundle applies: commit to 3 months and receive 10% off plus 12 complimentary Skinny Shots.
At Lily Lane Aesthetics, tirzepatide is available from $550/month (Tier 1) or $700/month (Tier 2). A 3-month supply receives 10% off tier pricing plus 12 complimentary weekly skinny shots, a $360 value. Tier is determined by your dosing protocol, which your provider will establish during your consultation.
Clinical trials show tirzepatide produces greater average weight loss — up to 20% body weight reduction in some patient cohorts, compared to approximately 15% with semaglutide. Tirzepatide activates two receptor pathways (GIP and GLP-1) versus semaglutide's one (GLP-1), which likely accounts for the difference. That said, the best medication is the one that's right for your individual health profile — your provider will help you decide.
Most patients notice appetite suppression within the first week. Significant weight loss is typically visible within 4 to 6 weeks. Clinical trials showed the most substantial cumulative results between 12 and 36 weeks of consistent use. Duration and magnitude of results vary by individual, dose, and lifestyle factors.
The most commonly reported side effects are gastrointestinal — nausea, reduced appetite, and occasional digestive discomfort, most prominent during dose escalation. These typically diminish as the body adjusts. At Lily Lane, doses are titrated slowly to minimize the frequency and severity of these effects during the adjustment period.
Mounjaro is the brand-name version of tirzepatide approved for type 2 diabetes. Zepbound is the brand-name version approved specifically for chronic weight management. The active compound is the same. At Lily Lane, tirzepatide is administered within a supervised medical weight loss program tailored to your goals.
Yes. A medical consultation and in-house lab work are required before beginning any protocol. Labs are completed on-site at Lily Lane and results are returned within 24 hours — so your protocol can begin as quickly as you're cleared. No outside lab coordination is needed.
Tier 1 $550/mo · Tier 2 $700/mo · 3-month bundle: 10% off + 12 skinny shots.
Houston, TX · 713.487.9667 · @lilylanehouston